Biological agents and fracture risk


如何引用文章

全文:

详细

In patients with chronic inflammatory diseases, including rheumatic ones, the risk of fractures exceeds that in the population. Chronic inflammation is one of the most discussed and most important pathogenic factors of reduced bone mineral density (BMD), its worse quality and increased fracture risk. The chronic inflammatory process contributes to the imbalance of bone remodeling toward bone resorption. The use of biological agents in patients with rheumatic and other autoimmune diseases effectively suppresses systemic inflammation and increases BMD. However, the effect of the biological agents in lessening the risk of fractures remains unproven.

参考

  1. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. Ревматология. Национальное руководство. Под ред. Е.Л. Насонова и В.А. Насоновой. М.: ГЭОТАР-Медиа; 2008:290-331.
  2. Беневоленская Л.И., Торопцова Н.В. Остеопороз. Ревматология. Национальное руководство. Под ред. Е.Л. Насонова и В.А. Насоновой. М.: ГЭОТАР-Медиа; 2008:589-608.
  3. Kim SY, Schneeweiss S, Liu J, Daniel GW, Ghang CL, Garneau K, Solomon DH. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12:R154.
  4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54:49-52.
  5. Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis. 2001;60:521-522.
  6. Аmin S, Gabriel SE, Achenbach SJ, Atkinson EJ, Melton LJ. Are young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based study. J Rheumatol. 2013;40;1669-1676.
  7. Başkan BM, Sivas F, Alemdaroflu E, Duran S, Özoran K. Association of bone mineral density and vertebral deformity in patients with rheumatoid arthritis. Rheumatol Int. 2007;27:579-584.
  8. Maghraoui A El, Rezqi A, Mounach A, Achemlal L, Bezza A, Ghozlani I. Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. Rheumatology. 2010;49:1303-1310.
  9. Brennan SL, Toomey L, Kotowicz MA, Henry MJ, Griffiths H, Pasco JA, Brennan Е. Rheumatoid arthritis and incident fracture in women: a case—control study. BMC Musculoskeletal Disorders. 2014;15:13.
  10. Dirven L, van den Broek M, van Groenendael JHLM, de Beus WM, Kerstens PJSM, Huizinga TWJ, Allaart CF, Lems WF. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskeletal Disorders. 2012;13:125.
  11. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case-control study with 53,108 patients with fracture. J Rheumatol. 2010;37:2247-50.
  12. Vosse D, Landewé R, van der Heijde D, van der Linden S, van Staa T-P, Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis. 2009;68:1839-1842.
  13. Hiroshi T. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature Rev Immunol. 2007;7:292-304.
  14. Berek C, Schroder AE. A germinal center-like reaction in the nonlymphoid tissue of the synovial membrane. Annals New York Academy of Sciences. B-Lymphocytes and Autoimmunity. 1997;815:211-217.
  15. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Lasker Clinical Medical Research Award. Nat Med. 2003;9(10):1245-1250.
  16. Tashjian AH Jr, Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L. Tumor necrosis factor — (Cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology. 1987;120:2029-2036.
  17. Novack DV, Ross FP, Teitelbaum SL, Kitaura H, Zhou P, Kim HJ. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest. 2005;115:3418-3427.
  18. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143:123-150.
  19. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627-1652.
  20. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T. Interleukin 1 induces multinucleation and bone resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res. 1999;247:84-93.
  21. Sato K, Fujii Y, Asano S, Ohtsuki T, Kawakami M, Kasono K, Tsushima T, Shizume K. Recombinant human interleukin 1 and stimulate mouse osteoblast-like cells (MC3T3—E1) to produce macrophage-colony stimulating activity and prostaglandin E2. Biochem Biophy Res Comm. 1986;141:285-291.
  22. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 1990;4:2860-2867.
  23. Feyen JH, Elford P, Di Padova FE, Trechsel U. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J Bone Miner Res. 1989;4:633-638.
  24. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC. 17 Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883-891.
  25. Roodman GD. Interleukin-6: an osteotropic factor? J Bone MinerRes. 1992;7:475-478.
  26. Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-B (RANK) ligand/RANK system. Endocrinology. 2005;146:1991-1998.
  27. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1-7.
  28. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345-1352.
  29. Lubberts E, Van Den BL, Oppers-Walgreen B, Schwarzenberger P, Coenen-De Roo CJ, Kolls JK, Joosten LA, Van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-B ligand/osteoprotegerin balance. J Immunol. 2003;170:2655-2662.
  30. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345-1352.
  31. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood. 2000;96:1873-1878.
  32. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. AnnuRev Immunol. 2007;25:221-242.
  33. Miranda-Carus ME, ito-Miguel M, Balsa A, Cobo-Ibanez T, Perez De AC, Pascual-Salcedo D, Martin-Mola E. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum. 2006;54:1151-1164.
  34. Rothe L, Collin-Osdoby P, Chen Y, Sunyer T, Chaudhary L, Tsay A, Goldring S, Avioli L, Osdoby P. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998;139:4353-4363.
  35. Takahashi N, Mundy GR, Roodman GD. Recombinant human interferon-inhibits formation of human osteoclast-like cells. J Immunol. 1986;137:3544-3549.
  36. Amcheslavsky A, Bar-Shavit Z. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. J Cell Physiol. 2006;207:244-250.
  37. Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H, Kawase Y, Hoshino T, Yokota K, Kuzuhara A, Nakamura M. Interferon-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001;44:275-285.
  38. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:885-906.
  39. Cottrell J, O’Connor JP. Effect of non-steroidal antiinflammatory drugs on bone healing. Pharmaceuticals. 2010;3:1668.
  40. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis. 1995;54:801-806.
  41. Lange U, Teichmann J, Müller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-a antibody: a prospective open-label pilot study. Rheumatology. 2005;44:1546-1548.
  42. Keat A, Barkham N, Bhalla A, Gaffne K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P. BSR guidelines for prescribing TNF-a blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology. 2005;44:939-947.
  43. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.
  44. Kawai VK, Grijalva CG, Arbogast PG, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchell EF Jr, Stein CM, Griffin MR. Initiation of Tumor Necrosis Factor Alpha (TNFα) antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res. 2013;65(7):1085-1094.
  45. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of Disease-Modifying Antirheumatic Drugs on тonvertebral аracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Mineral Res. 2012;27(4):789-796.
  46. Roussy P, Bessette L, Bernatsky S, Rahme E, Lachaine J. Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. Osteoporos Int. 2013;24(9):2483-2492. doi: 10.1007/s00198-013-2321-x.
  47. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15(4):155-160.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2015

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##